| Negative for HPV 6/11/16/18 at enrollment and to 1 mo after 3rd injection; received all doses
(per-protocol analysis)
|
98%
(86%–100%)
for lesions associated with HPV 16 or 18 |
| Negative for HPV 6/11/16/18 at enrollment
(unrestricted susceptible population analysis)
|
95%
(85%–99%)
for lesions associated with HPV 16 or 18 |
| All randomized subjects, including those positive for HPV 6/11/16/18 at enrollment
(intention-to-treat analysis)
|
44%
(26%–58%) for lesions associated with HPV 16 or 18
|
| All randomized subjects, including those positive for HPV 6/11/16/18 at enrollment
(intention-to-treat analysis)
|
17% (1%–31%) for lesions associated with any HPV type |
